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ObestatinObestatin is a 23-amino acid gut-derived neuropeptide, encoded by the same gene with ghrelin. The goal of this
studywas to examine the effects of obestatin on the acute and chronic analgesic actions ofmorphine and onmild
morphine withdrawal. Open-ﬁeld (OF) and elevated plus maze (EPM) tests were used to assess mild morphine
withdrawal-induced behavior changes and the heat-radiant tail-ﬂick assay was used to investigate analgesic
actions of morphine. CFLPmalemice were treated twice a daywith graded doses of morphine in EPM and OF ex-
periments and once a day in tail-ﬂick studies. Obestatin (1.5 μg/2 μl) was administrated once a day in all exper-
iments. Furthermore, 0.2 mg/kg naloxone or saline was administered after the ﬁnal injection of morphine at a
dose of 20 mg/kg in EPM and OF. These behavioral parameters were monitored in the OF: the percentage of cen-
ter ambulation time and distance; whereas in the EPM: the time spent in open arms and the entries into open
arms compared to the total time (%OAT) and entries (%OAE). In the OF, obestatin signiﬁcantly decreased the per-
centage of time spent in the center in mice undergoing naloxone-precipitated mild morphine withdrawal. EPM
resultswere similar to openﬁeld, but obestatin hadno signiﬁcant effect on parametersmentioned above. Besides,
obestatin maintained the analgesic effect of morphine 90 and 120 min after morphine injection in mice treated
with morphine receiving obestatin compared to mice treated with morphine. In tolerance studies, obestatin di-
minished the analgesic tolerance to morphine on the 5th day. In this studywe conﬁrmed that obestatin reversed
the effect of mild morphine withdrawal and enhances the analgesic effect of morphine. These data suggest that
obestatinmay have a role in opioid-induced analgesia and in behavioral responses induced by opioidwithdrawal.
© 2013 Elsevier B.V. All rights reserved.1. Introduction
In 2005, a ghrelin-associated peptide derived from the preproghrelin
was discovered by Zhang et al. [1] and named obestatin. Obestatin was
puriﬁed from the rat stomach and was initially reported to reduce food
intake, gastric emptying and intestinal motility [1,2]. It was also charac-
terized as an activator of the orphan G protein-coupled GPR39 receptor
and was found to be the main ligand for it. The highest levels of GPR39
mRNA were detected by in-situ hybridization in the amygdala, the hip-
pocampus, and the auditory cortex,while lower levelswere found in sev-
eral other brain regions but surprisingly no expression of GPR39 was
found in the hypothalamus in mice [3]. GPR39 receptor has two splice
variants, GPR39-1a and GPR39-1b. GPR39-1a is expressed selectively in
the gastrointestinal tract, whereas GPR39-1b has awider expression pat-
tern, including nuclei in the central nervous system, for example theysiology, Faculty of Medicine,
Szeged, Hungary. Tel.: +36 62
bó).
Psychiatry, Faculty of Medicine,
ghts reserved.amygdala, and hippocampus [4]. Later studies reported that GPR39
may not have obestatin as a main ligand [5–7]. After these ﬁndings,
Zhang et al. conﬁrmed that their original result was unreproducible [8]
and subsequent results suggested that glucagon-like peptide-1 receptor
(GLP-1R) is the receptor of obestatin [9,10]. Moreover, a few in vitro
studies claimed that obestatin stimulated ERK1/2 phosphorylation,
in rat tumor somatotroph cells [11]; in human pancreatic islet micro-
endothelial cells [10]; in human β cells [9] and in human retinal pigment
epithelial cells [12].
In the past few years themetabolic and bodyweight-regulating effect
of obestatin has been investigated in detail, however, there are only a few
reports, which examined the role of obestatin in exploratory behavior
and its analgesic effect. A previous study on the EPM indicated that
obestatin induced the elevation of the %OAT and %OAE in rat [13]. These
data were later conﬁrmed by Ishitobi et al. [14]: intracerebroventricular
administration of antisense DNA for GPR39-1b caused anxiolytic-like
effect in rats in two different behavioral tests. The same research group
discovered that ghrelin decreased the %OAT in the EPM and increased
the ambulation time in the OF test in rats and neonatal chicks [15,16],
hence ghrelin exerts opposite effects on behavioral patterns. The role of
ghrelin in reward (see reviews in this issue: [17,18]) and in anxiety
(see review: [19]) are well-examined research areas, but the role of
obestatin in these research ﬁelds has not been clariﬁed yet.
Fig. 1. A, B: The effect of naloxone and obestatin on EPM behavior (%OAT and %OAE) in
mice treated with morphine. The graded doses of morphine (mg/kg, s.c. per injection)
or saline were given twice daily for 3 days (day 1, 10; day 2, 20; day 3, 40). On day 4, nal-
oxone (0.2 mg/kg) or salinewas administered 2 h after theﬁnal injection ofmorphine at a
dose of 20 mg/kg, and the EPM behavior was measured 5 min after naloxone injection.
Mice were also treated once a day with either obestatin (1.5 μg/2 μl) or aCSF i.c.v
15 min aftermorphine injection for 3 days. On day 4, obestatin or aCSFwas administrated
15 min prior to test. Numbers of mice: control: 8, mice treated with morphine: 9,
morphine withdrawal mice: 8, morphine withdrawal mice + obestatin: 7, mice treated
with obestatin: 8. Bars represent the %OAT (Fig. 1A) and the %OAE (Fig. 1B), vertical
lines on the top of the bars denote S.E. M. A *: P b 0.05 vs. control mice, mice treated
withmorphine andmice treatedwith obestatin. B *:P b 0.05 vs. controlmice,mice treated
with morphine and mice treated with obestatin.
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obestatin on morphine-induced analgesia and on mild morphine with-
drawal in mice using three behavioral methods.
2. Materials and methods
2.1. Animals
Male CFLP white mice (30 ± 5 g of weight) of an outbred strain
(Domaszék, Hungary) were used. They were kept under a standard
light–dark cycle (lights on between 07.00 and 19.00 h) with food and
water available ad libitum. The animalswere kept and treated according
to the rules of the Ethical Committee for the Protection of Animals in
Research (Faculty of Medicine, University of Szeged, Hungary).
2.2. Surgery
For intracerebroventricular (i.c.v.) cannulation, the mice were anes-
thetized with an intraperitoneal (i.p.) injection of Sodium Pentobarbital
(Nembutal®, Phylaxia-Sanoﬁ, Budapest, Hungary; 50 mg/kg), and a
polyethylene cannula was inserted into the right lateral cerebral ventri-
cle and cemented to the skull with cyanoacrylate-containing instant
glue. The experiments were started 4 days after i.c.v. cannulation.
Upon conclusion of the experiments, 10 μl of methylene blue were
injected into the cerebral ventricle of the decapitated animals and the
position of the cannula was inspected visually. The spread ofmethylene
blue throughout the ventricular space indicated that the whole amount
of obestatin got into the ventricles. Mice with improper cannula place-
ment were excluded from the ﬁnal statistical analysis.
2.3. Drugs
For intracerebroventricular (i.c.v.) treatments obestatin (Anaspec,
Inc.) was dissolved in artiﬁcial cerebrospinal ﬂuid (aCSF) and injected
in a volume of 2 μl. For testing the morphine effects, subcutan (s.c.)
morphine–HCl (Sigma-Aldrich) and naloxone–HCl (Sigma-Aldrich) in-
jections were used. Control mice received saline s.c. and aCSF i.c.v.
2.4. Elevated plus maze (EPM)
The elevated plus maze (EPM) is an accepted model for studying
anxiety-like behavior in mice [20]. Conditions that decrease time spent
in the open arms are associated with anxiety-like behavior, whereas in-
creased time spent in the open arms is associated with an anxiolytic ef-
fect. The EPM apparatus (Columbus Instruments, Columbus, Ohio, USA)
consists of four arms (87-mm wide, 155-mm long) elevated 63.8 cm
above the ground, with two arms enclosed by 16.3-cm-high opaque
walls and illuminated with a 60 W light situated 1 m above the maze.
The combination of height, luminosity and open space is assumed to in-
duce anxiety-like behavior in mice. Behavioral testing was conducted
between 10.00 and 12.00 h. Mice were carried to the experimental
room in their home cages and habituated to the laboratory for at least
30 min before testing. Only one EPM apparatus per testing room was
present. The apparatus was thoroughly cleaned with ethanol (96%)
andwater betweenmice.Micewere placed in the center of themaze fac-
ing toward an enclosed arm and behavioral activities were recorded for
10 min [21]. The following behavioral parameters were monitored: the
time spent in open arms and the entries into open arms compared to
the total time (%OAT) and entries (%OAE) and the total activity which
was deﬁned as the total number of crosses between any two arms.
2.4.1. The effect of naloxone and obestatin on EPM behavior in mice treated
with morphine
We used twice daily injections of ascending doses of morphine
(08.00 and 16.00 h.) as follows: day 1: 10 mg/kg, day 2: 20 mg/kg, day
3: 40 mg/kg or saline [22]. Micewere also treated once a daywith eitherobestatin (1.5 μg/2 μl, i.c.v.) or aCSF (i.c.v.) at 08.15 h. On the test day
(day 4) animals received a single dose of morphine (20 mg/kg, s.c.) or
saline (s.c.) at 08.00 h and either aCSF or obestatin (i.c.v.) was given at
09.45 h. Naloxone treatment in a dose of 0.2 mg/kg, s.c. preceded be-
havioral assessment by 5 min. The behavioral changes were measured
for 10 min 2 h after the ﬁnal morphine treatment with EPM [21,23].
The treatment of speciﬁc groups is described below (Figs. 1A, B, 2 and
Table 2).
Treatment protocol was the same in the open-ﬁeld.2.5. Open-ﬁeld (OF) test
Obestatin effects on mild morphine withdrawal were also tested by
the Conducta System (Experimetria Ltd., Budapest, Hungary). The appa-
ratus consists of ﬁve black-painted testing boxes (40 cm × 50 cm ×
50 cm each) set in an isolated room; the movements of mice were de-
tected by high-density arrays of infrared diodes. One animal was placed
in one box, the apparatus is able to test 5 mice at the same time and
there is no connection between them. The ﬂoor of the box was washed
with ethanol (96%), water and dried prior to the next animal testing. On
the test day,micewere transported to the testing roomand the percent-
age of time spent in the center and ambulation distances in the center
were recorded individually for each animal and separately for each box.2.5.1. The effect of graded doses of acute obestatin on OF behavior in mice
Obestatin was administrated i.c.v. at graded doses: 0.5–2 μg. Mice
were tested 15 min after the obestatin treatment for 10 min.2.5.2. The effect of naloxone on OF behaviors in mice treated with obestatin
Weused twice daily injections of saline. Micewere also treated once
a day with either obestatin (1.5 μg/2 μl, i.c.v., respectively) or aCSF
(i.c.v.) at 08.15 h. On the test day (day 4) animals received saline (s.c.)
at 08.00 h and either aCSF or obestatin (i.c.v.) was given at 09.45 h. Nal-
oxone treatment in a dose of 0.2 mg/kg, s.c. preceded behavioral assess-
ment by 5 min. The behavioral changes were measured 2 h after the
ﬁnal saline treatment in the OF. See the speciﬁc treatments under
Fig. 3A, B and Table 1.
Fig. 2.The effect of naloxone and obestatin onEPMbehavior (total activity) inmice treated
with morphine. Treatment protocol and numbers of mice were the same as Fig. 1A and B.
Bars represent the total activity; vertical lines on the top of the bars denote S.E. M.
79N. Lipták et al. / Regulatory Peptides 186 (2013) 77–822.6. Tail-ﬂick
Obestatin effect on morphine-evoked analgesic response was tested
by the tail-ﬂick system (IITC Life Science, California, USA) described by
[24]. All experiments were started with an initial tail-ﬂick latency mea-
surement, pain sensitivity was measured 15, 30, 60 min after peptide
challenge in acute dose–response experiments and 60, 90, 120 min
aftermorphine treatment in acutemorphine experiment (day 1). In tol-
erance studies, pain sensitivity was measured 60 min after morphine
injection. For tail-ﬂick measurement, animals were habituated to the
experimental roomat least 30 min prior to testing. During themeasure-
ment, they were loosely restrained and the tail was positioned so that
the light beam focused on the tail approximately 1–2 cm from the
base. Tail stimulation was delivered at different sites in consecutive
measures to prevent tissue damage. The analgesic effect was expressed
according to this equation:
analgesic effect %ð Þ ¼ TFn–TF0ð Þ= TFmax−TF0ð Þ  100;
where TF0 is the tail-ﬂick latency in the preliminary test mentioned
above or (in tolerance studies) before morphine injection. TFn is the
value of a repeated corresponding measurement n (15, 30, 60 or 60,
90, 120 min) after obestatin or/and morphine injection, and TFmax in-
dicates the cutoff (20 s).Table 1
The effect of naloxone and obestatin on OF behavior in mice.
Day 1 Day 2 Day 3
a.m. p.m. a.m. p.m. a.m.
1 Sal. + aCSF Sal. Sal. + aCSF Sal. Sal. + aCSF
2 Sal. + aCSF Sal. Sal. + aCSF Sal. Sal. + aCSF
3 Sal. + obestatin Sal. Sal. + obestatin Sal. Sal. + obestatin
Table 2
The effect of naloxone and obestatin on EPM and OF behavior in mice treated with morphine.
Day 1 Day 2 Da
a.m. p.m. a.m. p.m. a.m
1 Sal. + aCSF Sal. Sal. + aCSF Sal. Sal
2 M 10 mg/kg and aCSF M 10 mg/kg M 20 mg/kg and aCSF M 20 mg/kg M
3 M 10 mg/kg and aCSF M 10 mg/kg M 20 mg/kg and aCSF M 20 mg/kg M
4 M 10 mg/kg and obestatin M 10 mg/kg M 20 mg/kg and obestatin M 20 mg/kg M
5 Sal. + obestatin Sal. Sal. + obestatin Sal. Sal2.6.1. The analgesic effect of graded doses of acute obestatin
Obestatin was administrated i.c.v. at graded doses: 0.5–2 μg. Mice
were tested 15, 30 and 60 min after the obestatin treatment.
2.6.2. The effect of obestatin on analgesic effect induced by acute morphine
treatment (1st day)
Mice were treated 10 mg/kg morphine (s.c.) or saline (s.c.) at
09.00 h, an hour before the ﬁrst tail-ﬂick measurement. Obestatin or
aCSF were injected i.c.v. at 09.45 h. The analgesic response was mea-
sured 60, 90 and 120 min after the morphine injection.
2.6.3. The effect of obestatin on analgesic tolerance to morphine
To develop morphine tolerance, mice received either morphine
(10 mg/kg, s.c.) or saline twice daily for four days, at 09.00 and
16.00 h [25,26]. Mice were also treated with either obestatin or aCSF
once a day at 09.45 h. On the ﬁfth day, morphine was administrated
only in the morning at 09.00 h. Obestatin treatment was the same as
in the previous days. Analgesic effect was measured on the 1st, 3rd
and 5th days in the morning at 10.00 h.
2.7. Statistical analysis
Statistical analysis of the elevated plusmaze and open-ﬁeld datawas
made by one-way analysis of variance (ANOVA) followed by Sidak post-
hoc test. Tail-ﬂick experiments were analyzed using two-way repeated
measures ANOVA, where drug effect (between subjects), time effect
(within subjects) and their interactions were analyzed. In presence of
interactions between drug and time, drug differences depend on time
and vice versa, so in case of a signiﬁcant interaction, drug effects were
tested on each time point and time differences were tested in each
group by Sidak post-hoc test. A probability value, P b 0.05 was consid-
ered statistically signiﬁcant.
3. Results
3.1. The effect of naloxone and obestatin on EPM behavior in mice treated
with morphine
Obestatin alone had no effect on the EPM behavior compared to
control mice. Obestatin treated mice undergoing withdrawal showed
decreased tendency in both parameters (Fig. 1A, B) compared to theDay 4
p.m. 08.00–09.55 h
staggered
1 h 45 min later
staggered 09.45–11.45 h
1 h and 55 min later
staggered 09.55–12.00 h
Sal. Sal. aCSF Sal.
Sal. Sal. aCSF N: 0.2 mg/kg
Sal. Sal. Obestatin N: 0.2 mg/kg
y 3 Day 4
. p.m. 08.00–
09.55 h
staggered
1 h 45 min
later staggered
09.45–11.45 h
1 h and 55 min
later staggered
09.55–12.00 h
. + aCSF Sal. Sal. aCSF Sal.
40 mg/kg and aCSF M 40 mg/kg M 20 mg/kg aCSF Sal
40 mg/kg and aCSF M 40 mg/kg M 20 mg/kg aCSF N: 0.2 mg/kg
40 mg/kg and obestatin M 40 mg/kg M 20 mg/kg Obestatin N: 0.2 mg/kg
. + obestatin Sal. Sal. Obestatin Sal.
Fig. 3. A, B: The effect of naloxone and obestatin on OF behavior inmice treatedwithmor-
phine. Treatment protocol was the same as naloxone-precipitated mild withdrawal EPM
experiments. Numbers of mice: control: 12, mice treated with morphine: 8, morphine
withdrawal mice: 11, morphine withdrawal mice + obestatin: 10, mice treated with
obestatin: 11. Bars represent the percentage of ambulation distance in the center
(Fig. 3A) and the percentage of time spent in the center (Fig. 3B), vertical lines on the
top of the bars denote S.E. M. A *: P b 0.05 vs. control mice and mice treated with mor-
phine. B **: P b 0.05 vs. control mice, mice treated with morphine and morphine with-
drawal mice receiving obestatin.
Table 4
The effect of naloxone on OF behaviors in mice treated with obestatin.
Parameters in open-ﬁeld Saline + aCSF
(9)
Naloxone
(0.2 mg/kg) +
aCSF (9)
Naloxone
(0.2 mg/kg) +
obestatin
1.5 μg/2 μl (8)
The percentage of time spent
in the center ± S.E.M
7.65 ± 0.8 6.44 ± 0.33 5.69 ± 0.37
The percentage of ambulation
distances in the
center + S.E.M.
11.56 ± 1.44 10.56 ± 0.8 10.01 ± 1.12
Numbers in brackets show the numbers of mice used in these experiments.
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ences were not signiﬁcant (%OAT: [F(4,38) = 7.11, P b 0.086]; %OAE:
[F(4,38) = 7.11, P b 0.227]. Naloxone caused a signiﬁcant increase in
both parameters in morphine treated mice compared with control
mice and mice treated with morphine [F(4,38) = 11.01, P b 0.002].
Morphinewithdrawalmice receiving obestatin did not show signiﬁcant
changes in total activity compared to morphine withdrawal mice
[F(4,38) = 9.243, P b 0.682] (Fig. 2).
3.2. The effect of graded doses of acute obestatin on OF behavior in mice
The 1.5 μg/2 μl dose of obestatin had a moderate decreasing effect
on the percentage of time spent in the center compared to control
mice so this dose of obestatin was selected for the following experi-
ments. See the statistical data in Table 3.
3.3. The effect of naloxone on OF behavior in mice treated with obestatin
Naloxone alone had no effect on the percentage of time spent in the
center and ambulation distance in the center. Mice treated with nalox-
one and obestatin did not show any changes in these parameters. See
the statistical data in Table 4.
3.4. The effect of naloxone and obestatin on OF behavior in mice treated
with morphine
Obestatin alone had no signiﬁcant effect on both parameters
compared to control mice. Obestatin signiﬁcantly decreased the per-
centage of time spent in the center in mice undergoing naloxone-
precipitated mild morphine withdrawal [F(4,51) = 10.998, P b 0.045]
(Fig. 3B). Obestatin had no signiﬁcant effect on the percentage of
ambulation distance in center inmice treatedwithmorphine andnalox-
one [F(4,51) = 13.149, P b 0.998] (Fig. 3A). Naloxone precipitated mildTable 3
The effect of graded doses of acute obestatin on OF behavior in mice.
Parameters in open-ﬁeld aCSF control
(16)
Obestati
(15)
The percentage of time spent in the center ± S.E.M 6.77 ± 0.91 6.49 ± 0
The percentage of ambulation distances in the center ± S.E.M. 7.57 ± 0.81 6.89 ± 0
Numbers in brackets show the numbers of mice used in these experiments.morphine withdrawal caused signiﬁcant increase in both parameters
compared control mice and mice treated with morphine (the percentage
of time spent in the center: [F(4,51) = 10.998, P b 0.001]; the percentage
of ambulation distance in the center: Fig. 3A: [F(4,51) = 13.149,
P b 0.005]).
3.5. The analgesic effect of graded doses of acute obestatin
The 1.5 μg/2 μl dose of obestatin had a mild analgesic effect 15 min
after peptide administration compared to control mice [F(4,41) = 3.744,
P b 0.055], so this dose of obestatin and time-interval were selected for
the other tail-ﬂick experiments. Drug–time interactions: (drug–time
[F(4,41) = 2.260, P b 0.033]; time [F(4,41) = 4.001, P b 0.022]were signif-
icant; drug [F(4,41) = 1.910. P b 0.129] was not signiﬁcant. See the statis-
tical data in Table 5.
3.6. The effect of obestatin on analgesic effect induced by acute morphine
treatment (1st day)
Mice treatedwithmorphine showed signiﬁcant higher pain sensitivity
90 and 120 min aftermorphine injection compared to ﬁrst measurement
(60 min) of the same group [F(3,28) = 12.482, P b 0.001] and signiﬁcant
lower pain-related behavior compared with control in all time of mea-
surements. Obestatin maintained the analgesic effect of morphine 90
and 120 min after morphine injection in mice treated with morphine
receiving obestatin compared to mice treated with morphine (90 min:
[F(3,28) = 6.285, P b 0.01]; 120 min: [F(3,28) = 6.285, P b 0.001]. Drug–
time interactions (drug–time [F(3,28) = 7.198, P b 0.001]; time [F(3,28) =
7.912, P b 0.003]; drug [F(3,28) = 45.175, P b 0.003]) were signiﬁcant
(Fig. 4).
3.7. The effect of obestatin on analgesic tolerance to morphine
Morphine tolerant mice showed signiﬁcant higher pain sensitivity on
the 3rd and 5th days of experiments compared to the 1st day of the same
group [F(3,28) = 67.693, P b 0.001] and signiﬁcant lower pain-related be-
havior comparedwith control on the 1st and 3rd days, but not on the 5th
day. Morphine tolerant mice receiving obestatin displayed signiﬁcant
higher pain sensitivity on the 5th day compared with the 1st day of the
same group [F(3,28) = 8.693, P b 0.001]. Obestatin diminished the anal-
gesic tolerance tomorphine on the 5th day inmorphine tolerantmice re-
ceiving obestatin compared with morphine tolerant mice [F(3,28) =
8.693, P b 0.001]. Drug–time interactions (drug–time [F(3,28) = 15.813,n 0.5 μg/2 μl Obestatin 1.0 μg/2 μl
(15)
Obestatin 1.5 μg/2 μl
(10)
Obestatin 2.0 μg/2 μl
(15)
.68 5.71 ± 0.59 4.97 ± 1.3 6.31 ± 0.32
.88 6.85 ± 0.69 5.91 ± 1.2 6.31 ± 0.32
Table 5
The analgesic effect of graded doses of acute obestatin.
Analgesic
effect (%) ±
S.E.M
aCSF
control
(8)
Obestatin
0.5 μg/2 μl
(8)
Obestatin
1.0 μg/2 μl
(10)
Obestatin
1.5 μg/2 μl
(9)
Obestatin
2.0 μg/2 μl
(7)
15 min after
injection
3.26 ± 1.26 5.59 ± 1.06 6.25 ± 1.29 7.88 ± 0.93 2.53 ± 0.68
30 min after
injection
5.86 ± 1.47 5.86 ± 1.39 4.03 ± 1.53 8.64 ± 1.47 8.11 ± 1.83
60 min after
injection
5.38 ± 1.26 7.26 ± 1.37 6.15 ± 1.41 9.04 ± 1.48 5.43 ± 1.12
Fig. 5. The effect of obestatin on analgesic tolerance to morphine. Mice treated with mor-
phine at doses of 10 mg/kg or saline twice a day at 09.00 h and 16.00 h. Mice were also
given either obestatin (1.5 μg/2 μl) or aCSF i.c.v 15 min after morphine injection
(09.45 h) once a day on the test days and at 09.15 h on the other days. Tail-ﬂick latency
was measured 60 min after morphine treatment on the 1st, 3rd and 5th days. Numbers
of mice were the same as in Fig. 4. Bars represent the percentage of analgesic effect, verti-
cal lines on the top of the bars denote S.E. M., *: P b 0.05 vs. morphine tolerant mice and
control mice on the 5th day; #: P b 0.05 vs. morphine tolerant mice receiving obestatin
on the 1st day; ##: P b 0.05 vs. morphine tolerant mice on the 3rd and 1st day; ###:
P b 0.05 vs. morphine tolerant mice on the 1st day. Drug–time interactions (two-way
repeated measures ANOVA): drug–time [F(3,28) = 15.813, P b 0.001]; time [F(3,28) =
25.473, P b 0.003]; drug [F(3,28) = 62.100, P b 0.003].
81N. Lipták et al. / Regulatory Peptides 186 (2013) 77–82P b 0.001]; time [F(3,28) = 25.473, P b 0.003]; drug [F(3,28) = 62.100,
P b 0.003]) were signiﬁcant (Fig. 5).
4. Discussion
In this study the effect of obestatin on mild morphine withdrawal
and on analgesic action of morphine were investigated. Up to this
point, it has been a poorly examined research ﬁeld and the present
data may provide a new orientation for obestatin research.
It is known thatmorphine treatment alone andnaloxoneprecipitated
morphine withdrawal increase the ERK 1/2 phosphorylation in mice
[27,28]. Moreover, ERK 1/2 inhibitors can attenuate the analgesic effect
evoked by morphine [29,30] and block the increased open arm-time
aftermorphinewithdrawal on EPM [31]. There is no data about the effect
of obestatin on ERK 1/2 pathway in the central nervous system after
in vivo treatment, but obestatin might exert its effect on mild morphine
withdrawal and analgesia via regulation of ERK 1/2 pathway.
After chronic morphine treatment naloxone signiﬁcantly increased
the %OAT and %OAE compared to control mice and mice treated with
morphine in the EPM (Fig. 1A,B). Our result supports the previous ﬁnd-
ings described by [22]. The same experimental protocol was used in the
OF test. Mice undergoing mild withdrawal spent signiﬁcantly more
time and traveled signiﬁcantly more distance in the center of the open
ﬁeld compared to the control mice and mice treated with morphine
(Fig. 3A, B). To our knowledge this is the ﬁrst study which has con-
ﬁrmed this effect of naloxone-precipitated mild morphine withdrawal
in the open ﬁeld test in mice. In contrast to the data obtained in mice,
morphine administration increased %OAT and %OAE in rats [32–34]Fig. 4. The effect of obestatin on analgesic effect induced by acutemorphine treatment (1st
day). Mice treated with single injection of morphine at dose of 10 mg/kg or saline
(09.00 h). Mice were also given either obestatin (1.5 μg/2 μl) or aCSF i.c.v 45 min after
morphine injection (09.45 h). Tail-ﬂick latency was measured 60, 90, 120 min after mor-
phine treatment. Bars represent the percentage of analgesic effect, vertical lines on the top
of the bars denote S.E. M., *: P b 0.05 vs. mice treated with morphine and control mice at
90th min; **: P b 0.05 vs. mice treated with morphine and control mice at 120th min; #:
P b 0.05 vs. mice treated with morphine at 60th min; ##: P b 0.05 vs. mice treated with
morphine at 60th min and 90th min. Drug–time interactions (two-way repeated mea-
sures ANOVA): drug–time [F(3,28) = 7.198, P b 0.001]; time [F(3,28) = 7.912, P b 0.003];
drug [F(3,28) = 45.175, P b 0.003]. Numbers of mice: control: 7, mice treated with mor-
phine: 7, mice treated with morphine + obestatin: 8, mice treated with obestatin: 7.and decreased these parameters during morphine withdrawal [21,35].
In line with literature, naloxone alone did not alter the behavior of
mice in our experiments [22,36].
We injected obestatin 15 min prior to test in all experiments due to
our dose–response data and rapid degradation of obestatin [37].
Obestatin showed maximal levels of ERK1/2 phosphorylation after
15 min of obestatin treatment in vitro [11]. In accordancewith literature
[13], obestatin alone had no effect on total activity compared with con-
trol mice (Fig. 2). Morphine withdrawal mice receiving obestatin also
showed no signiﬁcant changes in total activity compared to morphine
withdrawal mice (Fig. 2). Chronic and acute administration of obestatin
alone had no signiﬁcant effect on EPM (Fig. 1A, B) and OF parameters
(Fig. 3A, B), so we cannot support the results of the mentioned study in
which obestatin caused a signiﬁcant increase in the time spent in open
arm in rats [13]. This contradiction alludes to the species-dependent im-
pact of obestatin, although the amino acid-sequence of rat and mouse
obestatin is completely the same. Obestatin displayed an inhibitory effect
on %OAT in EPM and the time spent and ambulation distance in the
center of the OF undergoing withdrawal. Although, our result was not
signiﬁcant in the EPM tests (P b 0.086), it followed the same tendency
that we have recorded in the open ﬁeld test after naloxone treatment.
The reduction of the analgesic effect of the single injection of mor-
phine and the analgesic tolerance to morphine were conﬁrmed using
tail-ﬂick assay. In tail-ﬂick we also recorded that obestatin signiﬁcantly
prolonged the analgesic effect of acute morphine 90 and 120 min after
morphine treatment (Fig. 4) and prevented the analgesic tolerance to
morphine in the ﬁfth day of chronic morphine treatment (Fig. 5).
The physiological role of obestatin in behavior and the underlying
mechanism have not been elucidated, so there has been no exact expla-
nation of these results yet. However, obestatin is produced by the
gastrointestinal tract, the peripheral obestatin might cross the blood–
brain barrier and enter the hippocampus and amygdala and by activat-
ing these brain regions theymaymodulate the behavior of rodents [13].
We administrated obestatin centrally in harmonywith previous studies
[38–41].
5. Conclusions
In conclusion, we observed that mice undergoing naloxone precipi-
tated mild morphine withdrawal showed increased %OAE and %OAT on
82 N. Lipták et al. / Regulatory Peptides 186 (2013) 77–82EPM and in the percentage of center ambulation time and distance in
OF. We also conﬁrmed that chronic administration of obestatin into
the central nervous system signiﬁcantly diminished these effects of nal-
oxone precipitated withdrawal in OF.We also discovered that obestatin
prevented the decrease of analgesic effect of acute morphine and the
analgesic tolerance to morphine in tail-ﬂick test.
Our data suggest that obestatin may have a physiological role in
anxiety and analgesia regulated by the opioid system.
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